GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » Additional Paid-In Capital

Dianthus Therapeutics (Dianthus Therapeutics) Additional Paid-In Capital : $475.86 Mil(As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Dianthus Therapeutics Additional Paid-In Capital?


Dianthus Therapeutics's quarterly additional paid-in capital increased from Sep. 2023 ($257.23 Mil) to Dec. 2023 ($258.23 Mil) and increased from Dec. 2023 ($258.23 Mil) to Mar. 2024 ($475.86 Mil).

Dianthus Therapeutics's annual additional paid-in capital increased from Dec. 2021 ($0.14 Mil) to Dec. 2022 ($1.66 Mil) and increased from Dec. 2022 ($1.66 Mil) to Dec. 2023 ($258.23 Mil).


Dianthus Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Dianthus Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dianthus Therapeutics Additional Paid-In Capital Chart

Dianthus Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Additional Paid-In Capital
0.14 1.66 258.23

Dianthus Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial 1.66 - 257.23 258.23 475.86

Dianthus Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Dianthus Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Dianthus Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Dianthus Therapeutics (Dianthus Therapeutics) Business Description

Traded in Other Exchanges
Address
7 Times Square, 43rd Floor, New York, NY, USA, 10036
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is comprised of an experienced team of biotech and pharma executives who are leading the next generation of antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune diseases.

Dianthus Therapeutics (Dianthus Therapeutics) Headlines